Share this article

SAR-442257 is under clinical development by Sanofi and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAR-442257’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SAR-442257 overview

SAR-442257 is under development for the treatment of relapsed and refractory multiple myeloma and relapsed and refractory non-Hodgkins lymphoma, diffuse large B-cell lymphoma (DLBCL), High-grade B-cell lymphomas (HGBCLs), transformed follicular lymphoma (tFL), follicular lymphoma (FL), non-Hodgkin lymphoma, mantle cell lymphoma (MCL), anaplastic large cell lymphoma (ALCL), nodal peripheral T cell lymphoma, angio-immunoblastic T cell lymphoma, adult T cell leukemia-lymphoma, extranodal natural killer cell lymphomas / T-Cell Lymphomas, cutaneous T cell lymphoma [CTCL], marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma, small lymphocytic lymphoma (SLL), T cell lymphoma (TCL), mycosis fungoides and Sezary syndrome. It is formulated as sterile lyophilised powder for solution and administered by intravenous route. It is a tri-specific monoclonal antibody that exhibit anti-neoplastic activity by targeting the CD28, CD38 and CD3. 

Sanofi overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.

For a complete picture of SAR-442257’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.